Alzheimer’s disease (AD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Alzheimer’s disease (AD)

Alzheimer’s disease (AD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Alzheimer's disease (AD) is a complex and heterogeneous neurodegenerative disorder, classified as either early onset (under 65 years of age), or late onset (over 65 years of age). Three main genes are involved in early onset AD: amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2). The apolipoprotein E (APOE) E4 allele has been found to be a main risk factor for late-onset Alzheimer's disease.

Epidemiology-

According to literature,in the US more than 6.2 million of all ages have Alzheimer's. An estimated 6.2 million Americans age 65 and older are living with Alzheimer's dementia in 2021. Seventy-two percent are 75 or older. One in nine people age 65 and older (11.3%) has Alzheimer's dementia.

Competitive landscape of Alzheimer’s disease (AD) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Alzheimer’s disease (AD) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Alzheimer’s disease (AD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Alzheimer’s disease (AD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                     Stage
1          Albumin           Grifols Biologicals, LLC Phase 3
2          ANAVEX2-73    Anavex Life Sciences Corp. Phase 3
3          AL002              Alector Inc. Phase 2
4          ACC-001          Pfizer Phase 2
5          Lecanemab      Biogen Phase 3
6          Idalopirdine     H. Lundbeck A/S Phase 3
7          AD-35 60mg group       Medpace, Inc. Phase 2
8          ORM-12741      Orion Corporation, Orion Pharma Phase 2
9          ASN51             Asceneuron Pty Ltd. Phase 1
10        ELND005          Elan Pharmaceuticals Phase 2